Evidence map›Paper›PMID 36257472›Full record

ArticleChest2023

Days Spent at Home and Mortality After Critical Illness: A Cluster Analysis Using Nationwide Data.

Guillaume L Martin, Alice Atramont, Marjorie Mazars, Ayden Tajahmady, Emin Agamaliyev, Mervyn Singer, Marc Leone, Matthieu Legrand

Open access · hybridAbstract read
In one paragraph

Article in Chest, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Article
  7. Article
  8. Review
  9. The times are changing: A primer on novel clinical trial designs and endpoints in critical care research.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2024
    Article
  10. Article
  11. Observational
  12. One-Year Survival and Hospital-free Days in Critical Illness After Viral Pneumonia.American journal of respiratory and critical care medicine · 2024
    Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Guillaume L MartinCaisse Nationale de l'Assurance Maladie, Paris, France.
Alice AtramontCaisse Nationale de l'Assurance Maladie, Paris, France.
Marjorie MazarsCaisse Nationale de l'Assurance Maladie, Paris, France.
Ayden TajahmadyCaisse Nationale de l'Assurance Maladie, Paris, France.
Emin AgamaliyevCaisse Nationale de l'Assurance Maladie, Paris, France.
Mervyn SingerBloomsbury Institute for Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom.
Marc LeoneAix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesia and Intensive Care Unit, Hospital Nord, Marseille, France; Société Française d'Anesthésie et de Réanimation (SFAR), Paris, France.
Matthieu LegrandSociété Française d'Anesthésie et de Réanimation (SFAR), Paris, France; Department of Anesthesia and Perioperative Care, Division of Critical Care Medicine, UCSF, San Francisco, CA; INI-CRCT network, Nancy, France. Electronic address: matthieu.legrand@ucsf.edu.
l'Assurance Maladie · FRAix-Marseille Université · FRBury College · GBSociété de Réanimation de Langue Française · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeyond the question of short-term survival, days spent at home could be considered a patient-centered outcome in critical care trials. RESEARCH QUESTION: What are the days spent at home and health care trajectories during the year after surviving critical illness? STUDY DESIGN AND

methodsData were extracted on adult survivors spending at least 2 nights in a French ICU during 2018 who were treated with invasive mechanical ventilation or vasopressors or inotropes. Trauma, burn, organ transplant, stroke, and neurosurgical patients were excluded. Stays at home, death, and hospitalizations were reported before and after ICU stay, using state sequence analysis. An unsupervised clustering method was performed to identify cohorts based on post-ICU trajectories.

resultsOf 77,132 ICU survivors, 89% returned home. In the year after discharge, these patients spent a median of 330 (interquartile range [IQR], 283-349) days at home. At 1 year, 77% of patients were still at home and 17% had died. Fifty-one percent had been re-hospitalized, and 10% required a further ICU admission. Forty-eight percent used rehabilitation facilities, and 5.7%, hospital at home. Three clusters of patients with distinct post-ICU trajectories were identified. Patients in cluster 1 (68% of total) survived and spent most of the year at home (338 [323-354] days). Patients in cluster 2 (18%) had more complex trajectories, but most could return home (91%), spending 242 (174-277) days at home. Patients in cluster 3 (14%) died, with only 37% returning home for 45 (15-90) days.

interpretationMany patients had complex health care trajectories after surviving critical illness. Wide variations in the ability to return home after ICU discharge were observed between clusters, which represents an important patient-centered outcome.

Indexed as

Critical CareCritical IllnessAdultCluster AnalysisHospitalizationHospitalsHumansintensive careoutcomePICStrajectory

Identifiers

PMID36257472
PMCPMC10107061
OpenAlexW4306411404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.